Howard Pringle

Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

Inhibition of endometrial carcinoma cell growth using antisense estrogen receptor oligodeoxyribonucleotides.

High BRAF mutation frequency does not characterize all melanocytic tumor types.

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

Characterization of E-cadherin-dependent and -independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition.

WNT5A expression increases during melanoma progression and correlates with outcome.

Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms.

Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Expression of tenascin-C and its isoforms in the breast.

Expression of CTGF and Cyr61 in colorectal cancer.

Prognostic tissue markers in melanoma.

Accurate detection of copy number changes in DNA extracted from formalin-fixed, paraffin-embedded melanoma tissue using duplex ratio tests.

Influence of plasma processing on recovery and analysis of circulating nucleic acids.

Plasticity of melanoma and EMT-TF reprogramming.

Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.

Novel plasma microRNA biomarkers for the identification of colitis-associated carcinoma.

microRNA-10b is a prognostic biomarker for melanoma.

5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma.

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.

Correction to: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.

Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.

Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery.

Exploration of Matrix Effects in Laser Ablation Inductively Coupled Plasma Mass Spectrometry Imaging of Cisplatin-Treated Tumors.

The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation.

Development of a patient-derived explant model for prediction of drug responses in endometrial cancer.

Evaluating and comparing immunostaining and computational methods for spatial profiling of drug response in patient-derived explants.